ArticleCancer discovery2021
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 198 citations in OpenAlex.
- Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer.Cancer discovery · 2026Article
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- Targeting the nervous system: Mechanistic insights into neuro-tumor communication and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
- Article
- Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.Experimental hematology & oncology · 2026Review
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer.Cancer research · 2026Article
- Cancer-associated fibroblast subtypes differentially modulate natural killer cells in cancer.Cell reports · 2026Article
- Glutamine-dependent changes in fibroblast-derived extracellular matrix dictate cancer cell behavior.Matrix biology : journal of the International Society for Matrix Biology · 2026Article
- Photothermal-detonated functional macrophage membrane-camouflaged nano-crackers induce tumor cell wandering-anoikis.Asian journal of pharmaceutical sciences · 2026Article
- Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy.Experimental hematology & oncology · 2026Review
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer.bioRxiv : the preprint server for biology · 2026Article
- Pancreatic cancer.Nature reviews. Disease primers · 2026Review
- Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.Genes & diseases · 2026Review
- Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1.Cancer research · 2026Article
- Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer.JCI insight · 2026Article
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
- Heterogeneity and plasticity of cancer-associated fibroblasts.Nature cancer · 2026Review
- Neuro-tumor interactions in peripheral tumors.Cancer metastasis reviews · 2026Review
- Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver.Experimental & molecular medicine · 2026Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 5 institutions in 1 country.
Ralph Francescone *Cancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Débora Barbosa Vendramini-Costa *Cancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0001-7617-4945
Janusz Franco-BarrazaCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0003-3652-5311
Jessica WagnerMolecular Therapeutics Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Alexander MuirKoch Institute for Integrative Cancer Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Allison N LauKoch Institute for Integrative Cancer Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Linara GabitovaMarvin and Concetta Greenberg Pancreatic Cancer Institute, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Tatiana PazinaBlood Cell and Development and Function Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Sapna GuptaCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Tiffany LuongCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Dustin RollinsCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Ruchi MalikCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Roshan J ThapaBlood Cell and Development and Function Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Diana RestifoMarvin and Concetta Greenberg Pancreatic Cancer Institute, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Yan ZhouMolecular Therapeutics Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kathy Q CaiCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Harvey H HensleyMolecular Therapeutics Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Yinfei TanCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Warren D KrugerCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0002-4990-3695
Karthik DevarajanBiostatistics and Bioinformatics Facility, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Siddharth BalachandranBlood Cell and Development and Function Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Andres J Klein-SzantoCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Huamin WangDivision of Pathology/Lab Medicine, Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wafik S El-DeiryMolecular Therapeutics Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-6702-4192
Suraj PeriBiostatistics and Bioinformatics Facility, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kerry S CampbellMarvin and Concetta Greenberg Pancreatic Cancer Institute, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0003-4665-7326
Igor AstsaturovMarvin and Concetta Greenberg Pancreatic Cancer Institute, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Edna CukiermanCancer Biology Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania. edna.cukierman@fccc.edu.ORCID 0000-0002-1452-9576
Fox Chase Cancer Center · USDana-Farber Cancer Institute · USMassachusetts Institute of Technology · USMay Institute · USThe University of Texas MD Anderson Cancer Center · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MTRAINING PROGRAM IN CANCER RESEARCHT32CA009035 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 1985 to 2020
$10.5MUnderstanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8MUnderstanding Psychosocial and Immunologic Responses in Indolent Lymphoproliferative DisordersR01CA194263 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CAMPBELL, KERRY S, FANG, CAROLYN Y. · 2016 to 2020
$3.2MAn integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skinR01CA232256 · NCI · WISTAR INSTITUTE · PI CUKIERMAN, EDNA, RAJ, ARJUN · 2019 to 2023
$3.0MAnalysis of cancer cell metabolism in diverse environmental conditionsR01CA201276 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VANDER HEIDEN, MATTHEW G., VITKUP, DENNIS · 2016 to 2020
$3.0M3D-Adhesion Stromagenesis in Cancer PermissivenessR01CA113451 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CUKIERMAN, EDNA · 2006 to 2016
$2.8MSynergistic targeting of cholesterol metabolism and EGFR signaling in cancerR01CA188430 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR · 2014 to 2018
$1.9MRegulation of glucose metabolism to allow tumor initiation and growthR01CA168653 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2013 to 2019
$1.9MStructural Plasticity and Functional Interactions of the Signaling Adapter NHERFR01GM116911 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI RODER, HEINRICH · 2016 to 2019
$1.6MOncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cellsR21CA231252 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ASTSATUROV, IGOR, CUKIERMAN, EDNA · 2019 to 2020
$437kHoward Hughes Medical InstituteNCI NIH HHS F32 CA213810NCI NIH HHS K99 CA234221NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA113451NCI NIH HHS R01 CA168653NCI NIH HHS R01 CA188430NCI NIH HHS R01 CA194263NCI NIH HHS R01 CA201276NCI NIH HHS R01 CA232256NCI NIH HHS R03 CA212949NCI NIH HHS R21 CA231252NCI NIH HHS R35 CA242379NCI NIH HHS T32 CA009035NIGMS NIH HHS R01 GM116911Worldwide Cancer Research 20-0081
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and lacks effective therapeutics. Therefore, it is of paramount importance to identify new targets. Using multiplex data from patient tissue, three-dimensional coculturing
Indexed as
AdenocarcinomaCarcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticHumansImmunosuppression TherapyNetrinsNutritional SupportPancreatic NeoplasmsTumor Microenvironmentnetrin-G1Netrins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.